These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35134091)

  • 1. The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate.
    Jung BK; An YH; Jang JJ; Jeon JH; Jang SH; Jang H
    PLoS One; 2022; 17(2):e0263684. PubMed ID: 35134091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS-CoV-2 neutralization.
    de Lima VA; Nunes JPS; Rosa DS; Ferreira R; Oliva MLV; Andreata-Santos R; Duarte-Barbosa M; Janini LMR; Maricato JT; Akamatsu MA; Ho PL; Schenkman S
    Immun Inflamm Dis; 2024 Jul; 12(7):e1353. PubMed ID: 39056544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.
    Geng Q; Tai W; Baxter VK; Shi J; Wan Y; Zhang X; Montgomery SA; Taft-Benz SA; Anderson EJ; Knight AC; Dinnon KH; Leist SR; Baric RS; Shang J; Hong SW; Drelich A; Tseng CK; Jenkins M; Heise M; Du L; Li F
    PLoS Pathog; 2021 Sep; 17(9):e1009897. PubMed ID: 34492082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
    Tan TK; Rijal P; Rahikainen R; Keeble AH; Schimanski L; Hussain S; Harvey R; Hayes JWP; Edwards JC; McLean RK; Martini V; Pedrera M; Thakur N; Conceicao C; Dietrich I; Shelton H; Ludi A; Wilsden G; Browning C; Zagrajek AK; Bialy D; Bhat S; Stevenson-Leggett P; Hollinghurst P; Tully M; Moffat K; Chiu C; Waters R; Gray A; Azhar M; Mioulet V; Newman J; Asfor AS; Burman A; Crossley S; Hammond JA; Tchilian E; Charleston B; Bailey D; Tuthill TJ; Graham SP; Duyvesteyn HME; Malinauskas T; Huo J; Tree JA; Buttigieg KR; Owens RJ; Carroll MW; Daniels RS; McCauley JW; Stuart DI; Huang KA; Howarth M; Townsend AR
    Nat Commun; 2021 Jan; 12(1):542. PubMed ID: 33483491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model.
    Wongnak R; Brindha S; Oba M; Yoshizue T; Islam MD; Islam MM; Takemae H; Mizutani T; Kuroda Y
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.
    Routhu NK; Cheedarla N; Bollimpelli VS; Gangadhara S; Edara VV; Lai L; Sahoo A; Shiferaw A; Styles TM; Floyd K; Fischinger S; Atyeo C; Shin SA; Gumber S; Kirejczyk S; Dinnon KH; Shi PY; Menachery VD; Tomai M; Fox CB; Alter G; Vanderford TH; Gralinski L; Suthar MS; Amara RR
    Nat Commun; 2021 Jun; 12(1):3587. PubMed ID: 34117252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
    Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
    Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
    Fougeroux C; Goksøyr L; Idorn M; Soroka V; Myeni SK; Dagil R; Janitzek CM; Søgaard M; Aves KL; Horsted EW; Erdoğan SM; Gustavsson T; Dorosz J; Clemmensen S; Fredsgaard L; Thrane S; Vidal-Calvo EE; Khalifé P; Hulen TM; Choudhary S; Theisen M; Singh SK; Garcia-Senosiain A; Van Oosten L; Pijlman G; Hierzberger B; Domeyer T; Nalewajek BW; Strøbæk A; Skrzypczak M; Andersson LF; Buus S; Buus AS; Christensen JP; Dalebout TJ; Iversen K; Harritshøj LH; Mordmüller B; Ullum H; Reinert LS; de Jongh WA; Kikkert M; Paludan SR; Theander TG; Nielsen MA; Salanti A; Sander AF
    Nat Commun; 2021 Jan; 12(1):324. PubMed ID: 33436573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses.
    Wisnewski AV; Liu J; Lucas C; Klein J; Iwasaki A; Cantley L; Fazen L; Campillo Luna J; Slade M; Redlich CA
    PLoS One; 2022; 17(1):e0262657. PubMed ID: 35041700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
    Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
    Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.
    Pino M; Abid T; Pereira Ribeiro S; Edara VV; Floyd K; Smith JC; Latif MB; Pacheco-Sanchez G; Dutta D; Wang S; Gumber S; Kirejczyk S; Cohen J; Stammen RL; Jean SM; Wood JS; Connor-Stroud F; Pollet J; Chen WH; Wei J; Zhan B; Lee J; Liu Z; Strych U; Shenvi N; Easley K; Weiskopf D; Sette A; Pollara J; Mielke D; Gao H; Eisel N; LaBranche CC; Shen X; Ferrari G; Tomaras GD; Montefiori DC; Sekaly RP; Vanderford TH; Tomai MA; Fox CB; Suthar MS; Kozlowski PA; Hotez PJ; Paiardini M; Bottazzi ME; Kasturi SP
    Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34266981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice.
    Wang Z; Sun W; Li D; Sun Y; Zhu M; Wang W; Zhang Y; Li E; Yan F; Wang T; Feng N; Yang S; Xia X; Gao Y
    Virus Res; 2024 Jul; 345():199378. PubMed ID: 38643857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect
    Amanat F; Strohmeier S; Lee WH; Bangaru S; Ward AB; Coughlan L; Krammer F
    mBio; 2021 Aug; 12(4):e0100221. PubMed ID: 34311574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.
    Huang WC; Zhou S; He X; Chiem K; Mabrouk MT; Nissly RH; Bird IM; Strauss M; Sambhara S; Ortega J; Wohlfert EA; Martinez-Sobrido L; Kuchipudi SV; Davidson BA; Lovell JF
    Adv Mater; 2020 Dec; 32(50):e2005637. PubMed ID: 33111375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.